{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:01:02Z","timestamp":1784030462355,"version":"3.55.0"},"reference-count":56,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"Braeburn Pharmaceuticals"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2017,8,3]]},"DOI":"10.1080\/13696998.2017.1341416","type":"journal-article","created":{"date-parts":[[2017,6,10]],"date-time":"2017-06-10T14:06:28Z","timestamp":1497103588000},"page":"893-901","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8539-5352","authenticated-orcid":false,"given":"John A.","family":"Carter","sequence":"first","affiliation":[{"name":"EPI-Q Inc., Oak Brook, IL, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Dammerman","sequence":"additional","affiliation":[{"name":"Formerly of Braeburn Pharmaceuticals, Princeton, NJ, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Frost","sequence":"additional","affiliation":[{"name":"Eagleville Hospital, Eagleville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"key":"CIT0001","unstructured":"Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16-4984, NSDUH Series H-51); 2016. https:\/\/www.samhsa.gov\/data\/. Accessed November, 15 2016"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1036760"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1508490"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm655051e1"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2011.01075.x"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12183"},{"key":"CIT0007","doi-asserted-by":"crossref","first-page":"469","DOI":"10.18553\/jmcp.2005.11.6.469","volume":"11","author":"White AG","year":"2005","journal-title":"J Manag Care Pharm"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.06.005"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2015.1010031"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-012-9402-5"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-016-2897-0"},{"key":"CIT0012","unstructured":"SAMHSA Advisory. An introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence; 2012. http:\/\/store.samhsa.gov\/shin\/content\/\/SMA12-4682\/SMA12-4682.pdf. Accessed November 15, 2016"},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5694\/j.1326-5377.2007.tb00840.x","volume":"186","author":"Gibson AE","year":"2007","journal-title":"Med J Aust"},{"key":"CIT0014","unstructured":"FDA News Release. FDA approves first buprenorphine implant for treatment of opioid dependence. Silver Spring, MD: FDA. 2016. http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm503719.htm. Accessed May 26, 2016"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.9382"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.03.008"},{"key":"CIT0017","unstructured":"Bebinger M. The promise and price of new addiction treatment implant. WBUR; 2016. http:\/\/www.wbur.org\/commonhealth\/2016\/05\/19\/probuphine-opioid-treatment-implant. Accessed May 19, 2016"},{"key":"CIT0018","unstructured":"Bebinger M. FDA considering pricey implant as treatment for opioid addiction. National Public Radio (NPR); 2016. http:\/\/www.npr.org\/sections\/health-shots\/2016\/05\/20\/478577515\/fda-considering-pricey-implant-as-treatment-for-opioid-addiction. Accessed May 20, 2016"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2007.04.003"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.02.002"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.3109\/15360288.2015.1135847"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.3310\/hta11090"},{"key":"CIT0023","unstructured":"NIDA. Principles of drug addiction treatment: A research-based guide, 3rd edition. NIDA; 2012. https:\/\/d14rmgtrwzf5a.cloudfront.net\/sites\/default\/files\/podat_1.pdf. Accessed April 6, 2017"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-011-1962-8"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2016.1198798"},{"key":"CIT0026","first-page":"1964","volume":"49","author":"Clark RE","year":"2014","journal-title":"Health Serv Res"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.07.013"},{"key":"CIT0028","unstructured":"United States Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers. 2016. https:\/\/data.bls.gov\/cgi-bin\/dsrv?cu. Accessed February 1, 2017"},{"key":"CIT0029","unstructured":"Koerkamp BG. Uncertainty in medical decision making. Rotterdam, The Netherlands: Erasmus University; 2009. https:\/\/repub.eur.nl\/pub\/17360\/091201_GrootKoerkamp,Bas.pdf. Accessed November 15, 2016"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-014-0102-0"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.07.2783"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2013.0158"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.3109\/15360288.2015.1101641"},{"key":"CIT0034","first-page":"A214","volume":"17","author":"Rice J","year":"2014","journal-title":"Value Health"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12147"},{"key":"CIT0036","first-page":"1","volume":"53","author":"McCue MJ","year":"2016","journal-title":"Inquiry"},{"key":"CIT0037","first-page":"871","volume":"19","author":"Tkacz J","year":"2013","journal-title":"Am J Manag Care"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2003.00541.x"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.08.003"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2016.1139427"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.05.021"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.06.058"},{"key":"CIT0043","unstructured":"US Food and Drug Administration. Briefing document for the FDA Advisory Committee Meeting held December 11, 2015. Silver Spring, MD:US FDA; 2015. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PsychopharmacologicDrugsAdvisoryCommittee\/UCM480733.pdf. Accessed November 15, 2016"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2010.00274.x"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.04.008"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.03.039"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2016.1201509"},{"key":"CIT0048","unstructured":"Braeburn Pharmaceuticals. Braeburn Pharmaceuticals announces commercialization plans for Probuphine (buprenorphine) implant, six-month treatment for opioid dependence. Braeburn Pharmaceuticals; 2016. https:\/\/braeburnpharmaceuticals.com\/category\/press-release\/. Accessed February 1, 2017"},{"key":"CIT0049","unstructured":"Massachusetts Executive Office of Health and Human Services. List A: Opioids without abuse-deterrent properties. 2016. http:\/\/www.mass.gov\/eohhs\/docs\/dph\/quality\/drugcontrol\/drug-formulary\/2016-meetings\/cost-info-long-lasting-opioids-040716.pdf. Accessed February 15, 2017"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.4.308"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.3109\/15360288.2013.803511"},{"key":"CIT0052","unstructured":"Lee J. The costs of drug rehab. Drug Rehab 2013. http:\/\/www.choosehelp.com\/topics\/drug-rehab\/the-costs-of-drug-rehab. Accessed February 1, 2016"},{"key":"CIT0053","unstructured":"Institute for Clinical and Economic Review. Management of patients with opioid dependence: A review of clinical, delivery system, and policy options; 2014. http:\/\/icer-review.org\/wp-content\/uploads\/2016\/01\/CEPAC-Opioid-Dependence-Final-Report-For-Posting-July-211.pdf. Accessed November 15, 2016"},{"key":"CIT0054","unstructured":"US Census Bureau. Income Data Tables; 2016. https:\/\/www.census.gov\/topics\/income-poverty\/income.html. Accessed June 1, 2017"},{"key":"CIT0055","unstructured":"Lengyel T, Brown M. Everyone pays: A social cost analysis of incarcerating parents for drug offenses in Hawai\u2019i; 2009. https:\/\/caphawaii.files.wordpress.com\/2012\/07\/everyonepays_full.pdf. Accessed November 15, 2016"},{"key":"CIT0056","unstructured":"Centers for Medicare and Medicaid Services. CY 2017 Physician Fee Schedule Final Rule. 2017. https:\/\/www.cms.gov\/medicare\/medicare-fee-for-service-payment\/physicianfeesched\/. Accessed February 1, 2017"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2017.1341416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T13:42:39Z","timestamp":1659102159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2017.1341416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8,3]]}},"alternative-id":["10.1080\/13696998.2017.1341416"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2017.1341416","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}